TL/DR –
A study led by David Anderson, assistant professor of health services policy and management, analyzed responses of insurers to changes in Medicare Part D plans brought about by the 2022 Inflation Reduction Act. The Act introduced two major changes: a cap of $2,000 on out-of-pocket drug costs, down from $3,800, and a redistribution of costs after the cap is met, increasing insurers’ liability from 20% to 60%. The study found that insurers responded by lowering premiums, increasing deductibles, slightly limiting drug coverage, and reducing the number of plans available, but did not make significant changes to avoid insuring individuals with expensive drug needs.
Health services policy and management assistant professor David Anderson recently spearheaded a study to understand the changes that insurers have made to Medicare Part D plans, considering the introduction of the 2022 Inflation Reduction Act. The research, published in Health Affairs, finds that insurers primarily responded to the Act by reducing premiums and raising deductibles.
Anderson explained that the Medicare system often seems fragmented and complex, with different aspects administered by a mixture of federal government, private insurers, and pharmacy networks. According to him, insurers mostly respond to policy alterations by exiting markets, hiking premiums, or reducing plan generosity. Through this research, the team wanted to compare these typical reactions with how insurers have responded to the 2022 Inflation Reduction Act.
How the Inflation Reduction Act Altered Medicare Part D
The Inflation Reduction Act introduced two key changes to Medicare Part D. Firstly, it set a cap of $2,000 on out-of-pocket drug costs, a substantial drop from the $3,800 cap in 2024, and the limitless beneficiary responsibility in place in 2023 and the years before. The second alteration involved redistributing the residual costs after reaching the $2,000 out-of-pocket maximum. The Act increased insurers’ responsibility from 20% to 60%, reducing governmental spending from 80% to 20%, with drug manufacturers covering the leftover 20% of catastrophic expenses.
Anderson’s team assessed these policy changes’ impact by examining variations in premiums, deductibles, drug coverage, restrictions on drugs, and pharmacy networks. The critical question was, what strategies did insurance firms adopt to handle the heightened financial risk they took on due to this new policy?
Notable Findings of the Study
The study revealed a slight decrease in premiums, resulting in lower-than-anticipated monthly expenditure and fairly manageable preliminary costs. The researchers had forecasted a rise in deductibles, which did occur, even exceeding expectations. This made out-of-pocket expenses higher before the coverage came into force.
Drug coverage narrowed marginally, implying that some cheaper or preferred drugs might no longer be available. Changes to restrictions and pharmacy networks were not particularly noteworthy. However, the number of available plans did reduce, suggesting that some insurers chose to exit the marketplace.
Anderson concluded by stating, “By comparing the first year of available data to what things would have looked like without the Inflation Reduction Act, we found that insurers appear to be rebalancing their plans by shifting beneficiary costs from monthly payments to upfront payments. We expected more significant alterations to plan designs such as changes that would help them avoid insuring individuals with expensive drug needs, but we have not seen that shift so far. As the policy environment evolves, insurers may respond by changing strategies, so it’s important to continue monitoring the Medicare Plan D market to ensure that beneficiaries continue to experience relief from high prescription drug costs.”
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
—
Read More US Economic News